-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Junshi Biotech announced that the clinical trial application for JS026 injection has been approved by the Food and Drug Administration for the prevention and treatment of new coronavirus pneumonia (COVID-19)
.
JS026 injection is a recombinant fully human monoclonal antibody, mainly used for the prevention and treatment of new coronary pneumonia
.
JS026 targets the S1 subunit of the SARS-CoV-2 spike protein, binds to the receptor binding domain (RBD) with high affinity, and blocks the binding of RBD to the host cell surface receptor angiotensin converting enzyme 2 (ACE2), thereby Further block SARS-CoV-2 from infecting host cells
.
JS026 is screened from a single memory B cell in the body of COVID-19 recovered patients, and does not bind to the body's own antigens, so it has a low possibility of producing drug-resistant antibodies and toxic side effects
.
The binding epitope of JS026 is located in the relatively conserved region of RBD, and almost does not overlap with the RBD/ACE2 interaction site.
So far, no RBD mutation has been found to affect the binding of JS026, and it is expected to become a neutralizing antibody for most virus strains
.
The difference between the neutralizing antibody and the vaccine is that the vaccine induces the body to produce spontaneous immunity, while the neutralizing antibody is directly used to block the infection of human cells by the new coronavirus
.
JS026 can target the new coronavirus to accurately attack, thereby preventing the virus from entering the cell
.
After entering clinical trials, JS026 and esvirizumab have the potential to be used in combination to effectively deal with various viral mutations
.
End reference materials: [1] https://finance.
ifeng.
com/c/8BKIXHMxvfs selected in the past to watch the heavyweight! The new crown special medicine is coming out after a long time, or it will be listed before the end of the year.
Stem cell therapy for hair loss has been launched.
The second case of AIDS patient who has recovered without treatment has been found in the world! How far is it from us to cure AIDS? Rewenhua Shenzhi Pharmaceutical and Tsinghua team achieved a new breakthrough in the research and development of new crown antibodies | Drug Targets | Healthy Life | Pharmaceutical News | Drug Inventory | Pharmaceutical Technology | Basic Research on Drug Side Effects/Translational Medicine Leukemia | Lung Cancer | Gastric Cancer | Colorectal Cancer | Liver Cancer | Breast Cancer | Pancreatic Cancer | Cardiovascular Diseases | Neurodegeneration Diseases | Intestinal microbial medical devices/biotechnology in vitro diagnostics | Medical devices | Bio-nano | 3D printing | Gene testing | Single cell sequencing | Gene editing | Assisted reproduction | Artificial intelligence | Precision medicine policy Anticancer drugs | 4+7 belt quantity Procurement | Consumables | Filing System | Registrant System | Healthy China | New Edition of Essential Medicine Catalog | AI Medical Devices | Telemedicine | Same Equity Different Rights Market/Capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | Entrepreneurship Board| R&D Investment| Acquisitions| Market & Consumption
.
JS026 injection is a recombinant fully human monoclonal antibody, mainly used for the prevention and treatment of new coronary pneumonia
.
JS026 targets the S1 subunit of the SARS-CoV-2 spike protein, binds to the receptor binding domain (RBD) with high affinity, and blocks the binding of RBD to the host cell surface receptor angiotensin converting enzyme 2 (ACE2), thereby Further block SARS-CoV-2 from infecting host cells
.
JS026 is screened from a single memory B cell in the body of COVID-19 recovered patients, and does not bind to the body's own antigens, so it has a low possibility of producing drug-resistant antibodies and toxic side effects
.
The binding epitope of JS026 is located in the relatively conserved region of RBD, and almost does not overlap with the RBD/ACE2 interaction site.
So far, no RBD mutation has been found to affect the binding of JS026, and it is expected to become a neutralizing antibody for most virus strains
.
The difference between the neutralizing antibody and the vaccine is that the vaccine induces the body to produce spontaneous immunity, while the neutralizing antibody is directly used to block the infection of human cells by the new coronavirus
.
JS026 can target the new coronavirus to accurately attack, thereby preventing the virus from entering the cell
.
After entering clinical trials, JS026 and esvirizumab have the potential to be used in combination to effectively deal with various viral mutations
.
End reference materials: [1] https://finance.
ifeng.
com/c/8BKIXHMxvfs selected in the past to watch the heavyweight! The new crown special medicine is coming out after a long time, or it will be listed before the end of the year.
Stem cell therapy for hair loss has been launched.
The second case of AIDS patient who has recovered without treatment has been found in the world! How far is it from us to cure AIDS? Rewenhua Shenzhi Pharmaceutical and Tsinghua team achieved a new breakthrough in the research and development of new crown antibodies | Drug Targets | Healthy Life | Pharmaceutical News | Drug Inventory | Pharmaceutical Technology | Basic Research on Drug Side Effects/Translational Medicine Leukemia | Lung Cancer | Gastric Cancer | Colorectal Cancer | Liver Cancer | Breast Cancer | Pancreatic Cancer | Cardiovascular Diseases | Neurodegeneration Diseases | Intestinal microbial medical devices/biotechnology in vitro diagnostics | Medical devices | Bio-nano | 3D printing | Gene testing | Single cell sequencing | Gene editing | Assisted reproduction | Artificial intelligence | Precision medicine policy Anticancer drugs | 4+7 belt quantity Procurement | Consumables | Filing System | Registrant System | Healthy China | New Edition of Essential Medicine Catalog | AI Medical Devices | Telemedicine | Same Equity Different Rights Market/Capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | Entrepreneurship Board| R&D Investment| Acquisitions| Market & Consumption
